Dr Mo Yin
Infectious Diseases Physician
Bacterial Resistance Analysis Group
Dr Mo Yin is a highly motivated Infectious Diseases physician driven by the ideal of using quality clinical research to influence patient care and propel health policies. She has been active in epidemiological and clinical research, medical education, as well as hospital administration. She has received numerous awards for her achievements in clinical care, research and teaching. Dr Mo Yin’s career goal is to serve her community focusing on translational research to influence regional and global policies.
She is completed a DPhil in Clinical Medicine in 2022, during which she led a multi-centre randomised control trial to assess the impact of shortening treatment duration for ventilator-associated pneumonia.
Dr Mo Yin is currently the deputy director for the ADVANCE-ID research network, which focuses on conducting innovative and pragmatic large-scale randomised controlled trials for diagnosing and treating multidrug-resistant bacterial infections.
The potential impact of intensified community hand hygiene interventions on respiratory tract infections: a modelling study.
Pham TM. et al, (2022), Proceedings. Mathematical, physical, and engineering sciences, 478
Rapid diagnostics for antibiotic resistance: urgent need for strong clinical evidence.
Yin M., (2022), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
The effect of hand hygiene frequency on reducing acute respiratory infections in the community: a meta-analysis.
Mo Y. et al, (2022), Epidemiology and infection, 150
Effect of Delays in Concordant Antibiotic Treatment on Mortality in Patients With Hospital-Acquired Acinetobacter Species Bacteremia: Emulating a Target Randomized Trial With a 13-Year Retrospective Cohort
Lim C. et al, (2021), American Journal of Epidemiology, 190, 2395 - 2404
Effect of Delays in Concordant Antibiotic Treatment on Mortality in Patients With Hospital-Acquired Acinetobacter Species Bacteremia: Emulating a Target Randomized Trial With a 13-Year Retrospective Cohort.
Lim C. et al, (2021), American journal of epidemiology, 190, 2395 - 2404